RT Journal Article
SR Electronic
T1 SARS-CoV-2 Control on a Large Urban College Campus Without Mass Testing
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.01.21.21249825
DO 10.1101/2021.01.21.21249825
A1 O’Donnell, Chris
A1 Brownlee, Kate
A1 Martin, Elise
A1 Suyama, Joe
A1 Albert, Steve
A1 Anderson, Steve
A1 Bhatte, Sai
A1 Bonner, Kenyon
A1 Burton, Chad
A1 Corn, Micaela
A1 Eng, Heather
A1 Flage, Bethany
A1 Frerotte, Jay
A1 Balasubramani, Goundappa K.
A1 Haggerty, Catherine
A1 Haight, Joel
A1 Harrison, Lee H.
A1 Hartman, Amy
A1 Hitter, Thomas
A1 King, Wendy C.
A1 Ledger, Kate
A1 Marsh, Jane W.
A1 McDonald, Margaret C.
A1 Miga, Bethany
A1 Moses, Kim
A1 Newman, Anne
A1 Ringler, Meg
A1 Roberts, Mark
A1 Sax, Terrie
A1 Shekhar, Anantha
A1 Sterne, Matthew
A1 Tenney, Tyler
A1 Vanek, Marian
A1 Wells, Alan
A1 Wenzel, Sally
A1 Williams, John
YR 2021
UL http://medrxiv.org/content/early/2021/01/25/2021.01.21.21249825.abstract
AB Objective A small percentage of universities and colleges conduct mass SARS-CoV-2 testing. However, universal testing is resource-intensive, strains national testing capacity, and false negative tests can encourage unsafe behaviors.Participants A large urban university campus.Methods Virus control centered on three pillars: mitigation, containment, and communication, with testing of symptomatic and a random subset of asymptomatic students.Results Random surveillance testing demonstrated a prevalence among asymptomatic students of 0.4% throughout the term. There were two surges in cases that were contained by enhanced mitigation and communication combined with targeted testing. Cumulative cases totaled 445 for the term, most resulting from unsafe undergraduate student behavior and among students living off-campus. A case rate of 232/10,000 undergraduates equaled or surpassed several peer institutions that conducted mass testing.Conclusions An emphasis on behavioral mitigation and communication can control virus transmission on a large urban campus combined with a limited and targeted testing strategy.Competing Interest StatementJVW serves on Scientific Advisory Boards for ID Connect and Quidel, and an Independent Data Monitoring Committee for GlaxoSmithKline, none of which are related to this work.Funding StatementNo external funding was received.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Institutional Review Board of the University of Pittsburgh determined that the proposed activity is not research involving human subjects as defined by DHHS and FDA regulations.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData is available on public dashboard